Acobiom is a biotechnology company that specializes in the discovery of biomarkers and the development of innovative diagnostics, particularly in the field of precision medicine. One of their key products, GemciTest®, is a blood-based diagnostic test designed to predict patient responses to Gemcitabine, a chemotherapy treatment for pancreatic cancer. This test utilizes a combination of biomarkers, specifically a blood RNA signature, to identify patients who are most likely to benefit from this therapy. Acobiom's expertise extends to molecular biology, bioinformatics, and biostatistics, allowing them to provide comprehensive omics services that support translational medicine and life science research.

The company leverages over 20 years of experience in genomics and transcriptomics, employing advanced techniques such as RNA sequencing and PCR technologies. Their bioinformatics capabilities include the analysis of large sequencing datasets and the development of a substantial human RNA-Seq database. Acobiom's focus on precision medicine aims to optimize therapeutic interventions tailored to specific patient subpopulations, enhancing treatment efficacy and improving quality of life during therapy. Through partnerships and clinical trials, Acobiom continues to advance its mission of delivering innovative, non-invasive diagnostic solutions that personalize patient care in oncology.

France

Acobiom is specialized in the identification of new Biomarkers and in the development of innovative Diagnostics in Translational Research and Precision Medicine.

The company provides also customized services in genomics, transcriptomics, bioinformatics and biostatistics (data science), thanks to its technology platform and its scientific expertise.

For more information about Acobiom, please contact the company by email: busdev@acobiom.com, or visit its website: www.acobiom.com.
  

Acobiom

Company Details